Getting past execution risk is only one step on the road to becoming a sustainable independent big cap. As a company becomes profitable, investors expect it to bring in another substantial revenue-generating candidate. In 2013, execution is the name of the game for Onyx Pharmaceuticals Inc. It’s marketing its first wholly owned product, Kyprolis (carfilzomib), a treatment for refractory multiple myeloma (MM) patients, on its own in the US and major European countries. That’s a tallorder for a mid-cap biotech, but expectations are high, and if it succeeds, the company could become one of a handful of biotechs that evolve from R&D houses into fully integrated biopharmaceutical companies.
Already the company has made significant progress toward that goal; its market cap doubled to $5 billion in 2012. That’s because investors started to believe that the biotech is more...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on In Vivo for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?